biostudies-literatureUnknown10(11)Huang MFujian Provincial Health Technology ProjectNatural Science Foundation of Fujian ProvinceShigellosis is a serious public health issue in many developing countries. The emergence of multidrug-resistant (MDR) <i>Shigella</i> isolates has deepened the treatment difficulty and health burden of shigellosis. China is the largest developing country in the world, but so far, the genome of MDR <i>Shigella</i> isolates has not been well characterized. In this study, 60 clinical isolates of <i>Shigella</i> spp. in Fujian Province, southeast China, from 2005 to 2019 were characterized for drug resistance phenotype, whole-genome sequencing and bioinformatics analysis. The results showed that the MDR rate of <i>Shigella</i> isolates was 100%, among which the resistance rates of cefotaxime, ciprofloxacin and azithromycin were 36.67, 21.67 and 10.00 %, respectively. The positive rate of extenMicrobial genomicshttps://www.ebi.ac.uk/biostudies/studies/S-EPMC11893363biostudies-literatureGenome and antibiotic resistance characteristics of <i>Shigella</i> clinical isolates in Fujian Province, Southeast China, 2005-2019.PMC118933632022J013992021CXA024Qiu YYang JZhang XHuang MLuo CXu HfalseGenome and antibiotic resistance characteristics of <i>Shigella</i> clinical isolates in Fujian Province, Southeast China, 2005-2019.Shigellosis is a serious public health issue in many developing countries. The emergence of multidrug-resistant (MDR) <i>Shigella</i> isolates has deepened the treatment difficulty and health burden of shigellosis. China is the largest developing country in the world, but so far, the genome of MDR <i>Shigella</i> isolates has not been well characterized. In this study, 60 clinical isolates of <i>Shigella</i> spp. in Fujian Province, southeast China, from 2005 to 2019 were characterized for drug resistance phenotype, whole-genome sequencing and bioinformatics analysis. The results showed that the MDR rate of <i>Shigella</i> isolates was 100%, among which the resistance rates of cefotaxime, ciprofloxacin and azithromycin were 36.67, 21.67 and 10.00 %, respectively. The positive rate of exten2024-01-01T00:00:00Z2024 Nov2026-06-01T18:01:13.403Z2025-04-04T00:21:26.87ZS-EPMC118933633956508110.1099/mgen.0.001325